A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07283705
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • BMS-986504
  • MTAP-deleted Pancreatic Cancer
  • Phase 2 Study

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986504 — DRUG
    Given by po
  • Gemcitabine — DRUG
    Given by IV
  • Nab-paclitaxel — DRUG
    Given by IV
  • mFOLFIRINOX — DRUG
    Given by iv

Study Details

To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.

Key Dates

Start date
May 18, 2026
Status verified
Jun 2026
Primary completion
Oct 1, 2029
Completion
Oct 1, 2031

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Will receive a combination of BMS-986504, gemcitabine, and nab-paclitaxel for 4 treatment cycles.
  • Experimental: Cohort 2
    Will receive a combination of BMS-986504, gemcitabine, and nab-paclitaxel for 4-6 months, followed by Maintenance Therapy with BMS-986504 by itself for as long as the disease does not get worse.
  • Experimental: Cohort 3
    Will receive a combination of BMS-986504, and the combination treatment mFOLFIRINOX (oxaliplatin, irinotecan, and 5-fluorouracil) for 4-6 months.

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Maria P Morelli, MD
[email protected]
713-745-1297
Maria P Morelli, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies